Arlington-backed AVS Bio acquires UK bioreagent supplier Biorbyt in add-on deal
The deal expands AVS Bio’s product catalog and adds Biorbyt’s e-commerce distribution platform. Biorbyt will continue to operate under its existing leadership within the AVS Bio platform. AVS Bio is a portfolio company of Arlington Capital Partners, a Washington, D.C.-area investment firm.
The investment firm Arlington Capital Partners has announced an add-on acquisition for its portfolio company, AVS Bio. AVS Bio has acquired Biorbyt, a UK-based supplier specializing in bio-reagents, antibodies, proteins, and other biomaterials critical for life science research. This strategic move aims to broaden AVS Bio’s product offerings and enhance its global distribution capabilities. The acquisition specifically leverages Biorbyt's established e-commerce platform to reach a wider market. This deal marks an expansion for AVS Bio, a company based in Norwich, Connecticut, known for providing biological materials and services that support the development and manufacturing of vaccines, therapeutics, and biologics. The integration of Biorbyt is expected to bolster AVS Bio's position in the life science research supply chain. Biorbyt, established in 2011 and headquartered in Cambridge, UK, brings a substantial product catalog to AVS Bio. Its inventory includes over one million SKUs, encompassing a range of primary and secondary antibodies, recombinant and native proteins, ELISA kits, small molecules, and molecular biology reagents. This extensive catalog is a key asset in diversifying AVS Bio's overall portfolio and enhancing its service capabilities to researchers worldwide. Following the acquisition, Biorbyt will maintain its operational independence and continue under its current leadership team. This approach suggests a strategy to integrate Biorbyt’s existing strengths and operational model into the larger AVS Bio platform without immediate disruption to its management or day-to-day functions. The continuity of Biorbyt’s leadership indicates a focus on preserving its expertise and market presence within the life science sector. This acquisition by an Arlington Capital Partners-backed entity signals a continued trend of strategic consolidation within the life sciences and bioreagent supply sector. It suggests that private equity firms are actively seeking opportunities to create more comprehensive and globally distributed platforms to serve the growing demands of pharmaceutical research and biotechnology development. The focus on expanding product catalogs and e-commerce capabilities highlights the importance of diversified offerings and efficient global distribution in the modern life science supply chain.